Key facts
- Notable investors include China Cinda Investment, Xindahanshi Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Luye Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Luye Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luye Pharma
Manufacturer of pharmaceutical products intended to advance the development and production of anti tumor medications. The company offers proprietary oncology formulations such as liposomal paclitaxel and polysaccharide injectables, along with continued innovation in compound development and intelligent preparation technologies, enabling healthcare institutions and oncology practitioners to access reliable therapeutics that enhance treatment effectiveness.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2002
- Employees
- 725
- Website
- njluye.cn/
- Ownership
- Privately Held (backing)
Luye Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luye Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luye Pharma in its N-PORT filings yet. We sweep new filings monthly.